Anuh Pharma: Should You Buy, Hold, or Sell Right Now?

Anuh Pharma share price is up more than 11 percent today, trading around Rs 90 on the NSE, close to its 52-week high of Rs 93, well above its 52-week low of Rs 66.72. With a strong margin expansion story in Q1 FY27, investors are asking whether this API manufacturer is a stock to buy at the current discount, a hold, or a sell.

This Anuh Pharma stock analysis walks through the Q1 FY27 numbers, the shift toward higher-value regulated market products, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and investor communications.

Click Here – Get Free Investment Predictions

About Anuh Pharma

Before deciding on Anuh Pharma share price, it helps to understand the underlying business. Anuh Pharma Ltd. manufactures active pharmaceutical ingredients (APIs), holding USFDA and EU GMP certifications that support its growing presence in regulated global markets, with a manufacturing capacity of 2,400 MTPA at its Tarapur site.

The company has been successfully shifting from a high-volume bulk API supplier toward higher-value products targeting regulated markets, with export revenue rising to roughly Rs 88 crore from Rs 70 crore a year earlier and customer concentration easing as its top five customers fell to 20 percent of sales from 36 percent.

Anuh Pharma Share Price Today: Key Levels

The table below summarises where Anuh Pharma share price stands right now against its recent trading range and market value.

Metric	Value
Anuh Pharma CMP (NSE)	Rs 90.29
Anuh Pharma CMP (BSE)	Rs 91.00
52-Week High	Rs 93.00
52-Week Low	Rs 66.72
Market Capitalisation	Approximately Rs 814 crore
Dividend Yield	1.85%

Anuh Pharma share price surged today and is trading close to its 52-week high, reflecting strong investor response to the Q1 FY27 margin expansion story.

Check the Univest Screener for Live Stock Data

Anuh Pharma Financial Performance

The Anuh Pharma share price trend is closely tied to how these numbers evolve each quarter. Anuh Pharma reported Q1 FY27 (June 2026 quarter) standalone revenue from operations of Rs 193.81 crore, up 3.93 percent year on year from Rs 186.48 crore, with net profit surging 37.63 percent year on year to Rs 11.42 crore from Rs 8.30 crore. EBITDA rose 41.56 percent to Rs 19.36 crore, with margin expanding significantly to 9.99 percent from 7.34 percent a year earlier.

Production volume increased 19.46 percent to 491 metric tonnes, with profit before tax growing 54.55 percent to Rs 16.93 crore. Management reiterated its target of 15 to 20 percent annual growth over the medium term, supported by volume expansion and diversification in regulated global markets, alongside operational leverage from its USFDA and EU GMP certified facilities.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 193.81 crore	Rs 11.42 crore	+3.93% revenue, +37.63% profit YoY; margin to 9.99%

Valuation Check: Is Anuh Pharma Share Price Expensive?

Any view on Anuh Pharma share price should start from these valuation multiples. Anuh Pharma share price currently reflects a price to earnings ratio of about 18.42 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 50.8 times. The price to book ratio stands near 2.3 times, supported by an 11.65 percent return on equity.

Debt to equity of 0.00 means the company carries no debt. Given the strong margin expansion and successful shift toward higher-value regulated market products, this discount valuation could offer room for re-rating if the company delivers on its 15 to 20 percent medium-term growth target.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Anuh Pharma share price. Anuh Pharma share price is up more than 11 percent today, positioned close to its 52-week high of Rs 93, well above its 52-week low of Rs 66.72. A stock trading here, backed by very strong recent margin expansion, typically signals the market rewarding tangible execution in the company's shift toward higher-value products.

Trading volumes have picked up meaningfully today, so investors should track Anuh Pharma share price alongside continued margin trends and progress toward the company's 15 to 20 percent growth target in coming quarters, rather than reacting to today's single-day move alone at these technical levels.

Download the Univest iOS App or Univest Android App to track Anuh Pharma's live price and technical levels.

Shareholding Pattern

Shifts here can influence Anuh Pharma share price more than headline news on some sessions. Anuh Pharma is a promoter-led, debt-free API manufacturer with USFDA and EU GMP certifications. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Anuh Pharma

• Strong margin expansion: EBITDA margin expanded to 9.99 percent from 7.34 percent, with profit surging 37.63 percent year on year despite modest revenue growth.
• Successful shift toward higher-value products: The move toward regulated market products alongside easing customer concentration reflects durable strategic execution.
• Debt-free balance sheet: A debt to equity ratio of 0.00 gives the company significant financial flexibility.
• Confident management growth guidance: Management has reiterated a target of 15 to 20 percent annual growth over the medium term, supported by regulatory certifications and volume expansion.

Risks and Factors to Watch

• Modest revenue growth relative to profit growth: Revenue grew just 3.93 percent while profit surged 37.63 percent, showing much of the improvement has come from margin gains rather than topline expansion, which needs to broaden for sustained growth.
• Product line variability: Several product lines saw year-on-year declines even as overall profitability improved, indicating some unevenness across the portfolio.
• Tax demand and penalty order: The company received a tax demand and penalty order in June 2026, a regulatory matter worth monitoring.
• API sector competitive and regulatory pressure: Anuh Pharma competes against other domestic and international API manufacturers in a market subject to regulatory scrutiny.

Anuh Pharma Share Price Target: What the Data Suggests

Until then, Anuh Pharma share price remains best tracked through live, verified data rather than a single fixed number. Anuh Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering strong margin expansion and confident growth guidance, trading at a discount to the pharmaceutical sector.

Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.

Anuh Pharma: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Anuh Pharma share price right now. The Anuh Pharma buy or sell decision depends on whether the margin expansion and growth target are sustainable.

The case for buying: Value-focused investors who see the discount to sector PE combined with the strong margin expansion and management's confident growth guidance as attractive may find the current level, even after today's jump, worth considering.

The case for holding: Existing shareholders who already track Anuh Pharma's strategic shift toward regulated markets may prefer to stay invested and monitor continued execution.

The case for waiting: Investors wanting to see revenue growth broaden beyond margin gains before committing fresh capital may prefer to wait for that confirmation.

Historically, API manufacturers successfully shifting toward regulated, higher-value markets have rewarded patient investors, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Anuh Pharma share price surged today on strong Q1 FY27 margin expansion driven by a successful shift toward higher-value regulated market products, trading close to its 52-week high at a discount to the pharmaceutical sector. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Anuh Pharma a good stock to buy right now?

Ans. Anuh Pharma delivered strong Q1 FY27 margin expansion, with profit surging 37.63 percent year on year on modest revenue growth, driven by a shift toward higher-value regulated market products. The stock trades at a discount to the pharmaceutical sector, which may appeal to value-focused investors.

Q2. Why did Anuh Pharma's share price jump today?

Ans. Anuh Pharma share price jumped more than 11 percent today, likely reflecting continued positive investor sentiment following the company's strong Q1 FY27 margin expansion and confident growth guidance.

Q3. What is the Anuh Pharma share price today?

Ans. Anuh Pharma share price is trading around Rs 90 on the NSE, close to its 52-week high of Rs 93. The stock's 52-week low is Rs 66.72.

Q4. What is the Anuh Pharma share price target?

Ans. Anuh Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.

Q5. What does Anuh Pharma manufacture?

Ans. Anuh Pharma manufactures active pharmaceutical ingredients, holding USFDA and EU GMP certifications supporting its presence in regulated global markets.

Q6. What is Anuh Pharma's market capitalisation and PE ratio?

Ans. Anuh Pharma has a market capitalisation of approximately Rs 814 crore and trades at a price to earnings ratio of about 18.42 times, a discount to the pharmaceutical sector average PE of roughly 50.8 times.